Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Daiichi Pharmaceutical Co. Ltd.

www.daiichipharm.co.jp

Latest From Daiichi Pharmaceutical Co. Ltd.

From Whiskey To Cancer Drugs: George Nakayama’s Unusual Journey

From extricating Daiichi Sankyo from the Ranbaxy acquisition to enabling the rapid development of blockbuster Enhertu, George Nakayama has had a winding career path through multiple key strategic positions and decisions. He shares his experience and insights, and a good dose of humor, in this exclusive interview.

Leadership Strategy

BioNTech Eyes First Oncology Approvals By 2026

CEO U

Business Strategies ImmunoOncology

Five Key Takeaways From Merck’s Q2 Earnings Release

Keytruda and Gardasil lead Merck’s growth story, although Lagevrio’s ongoing decline placed a drag on quarterly performance. Lung cancer is driving Keytruda’s momentum outside the US.

Sales & Earnings Pricing Debate

Exelixis Looks To Early-Stage Option Rights As Low-Risk Pipeline Expansion Play

The maker of Cabometyx wants to expand its oncology pipeline via deal-making but is wary of the high attrition rate in cancer. Option deals with Cybrexa and Sairopa may avoid some of that risk.

Deals Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
UsernamePublicRestriction

Register